Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
11.85
-0.10 (-0.84%)
At close: Apr 28, 2026, 4:00 PM EDT
11.88
+0.03 (0.21%)
After-hours: Apr 28, 2026, 6:37 PM EDT
Kazia Therapeutics Revenue
Kazia Therapeutics had revenue of 14.66M AUD in the half year ending December 31, 2025, with 209,471,328.57% growth. This brings the company's revenue in the last twelve months to 885.77K, down -93.67% year-over-year. In the fiscal year ending June 30, 2025, Kazia Therapeutics had annual revenue of 1.83M, down -26.30%.
Revenue (ttm)
885.77K AUD
Revenue Growth
-93.67%
P/S Ratio
110.98
Revenue / Employee
147,628 AUD
Employees
6
Market Cap
135.41M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.83M | -652.76K | -26.30% |
| Jun 30, 2024 | 2.48M | 2.48M | 248,088.00% |
| Jun 30, 2023 | 1,000.00 | -24.00K | -96.00% |
| Jun 30, 2022 | 25.00K | -15.16M | -99.84% |
| Jun 30, 2021 | 15.19M | 14.19M | 1,426.13% |
| Jun 30, 2020 | 995.00K | -470.43K | -32.10% |
| Jun 30, 2019 | 1.47M | -11.64M | -88.82% |
| Jun 30, 2018 | 13.11M | 4.30M | 48.75% |
| Jun 30, 2017 | 8.81M | 4.74M | 116.46% |
| Jun 30, 2016 | 4.07M | 1.23M | 43.24% |
| Jun 30, 2015 | 2.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 35.58M |
| Innate Pharma | 10.57M |
| Alpha Cognition | 10.22M |
| Fate Therapeutics | 6.65M |
| Equillium | 4.39M |
| Connect Biopharma Holdings | 64.00K |
KZIA News
- 13 days ago - Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform - PRNewsWire
- 15 days ago - Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - PRNewsWire
- 3 months ago - Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) - PRNewsWire
- 3 months ago - Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer - PRNewsWire
- 3 months ago - Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End - PRNewsWire
- 4 months ago - Kazia Therapeutics Regains Full Nasdaq Listing Compliance - PRNewsWire
- 4 months ago - Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ - PRNewsWire
- 5 months ago - What's Going On With Cancer Firm Kazia Therapeutics - Benzinga